Table 1.
General characteristics of the study population [n = 317]
| Variable | Total |
|---|---|
| Demographics | |
| Age, years [median (IQR)] | 70 (9) |
| Sex, Female | 162 (51.1) |
| BMI, kg/m2 [median, IQR)] | 23.7 (4.8) |
| Underweight—BMI < 18.5 | 14 (4.5) |
| Normal—BMI 18.5–25.0 | 185 (58.3) |
| Overweight—BMI 25.0–30.0 | 96 (30.3) |
| Obese—BMI >30.0 | 22 (6.9) |
| Smoking, current or past | 179 (56.5) |
| Alcohol abuse, current or past | 45 (14.2) |
| FH of pancreatic cancer | 33 (10.4) |
| PH of other malignancies | 20 (6.3) |
| ASA score III–IV | 101 (31.8) |
| CACI ≥ 4 | 95 (30.0) |
| Rectal colonization by MDR bacteria | 27 (8.5) |
| Biliary stenting | 141 (44.5) |
| Weight loss | 192 (60.6) |
| Anemia | 108 (34.1) |
| Cholangitis within 6 weeks from surgery | 20 (6.3) |
| CA19-9 serum levels, U/mL [median (IQR)] | 98 (62) |
| Surgical data | |
| Pancreaticoduodenectomy | 199 (62.8) |
| Distal splenopancreatectomy | 97 (30.6) |
| Total pancreatectomy | 21 (6.6) |
| Minimally invasive approach | 31 (9.8) |
| Vascular resection | 22 (6.9) |
| Estimated blood loss [median (IQR)] | 420 (500) |
| Pathology data | |
| AJCC staging (8th edition) | |
| Stage I | 42 (13.2) |
| Stage II | 109 (34.4) |
| Stage III | 166 (52.4) |
| R status, R0 | 244 (76.8) |
| Lymph nodes examined [median (IQR)] | 39 (21) |
| N status | |
| N0 | 48 (15.1) |
| N1 | 104 (32.8) |
| N2 | 165 (52.1) |
Data are expressed as n (%) unless otherwise specified
CACI Charlson Age Comorbidity Index30, FH family history, PH personal history, IQR interquartile range, BMI body mass index, ASA American Society of Anesthesiologists, MDR multidrug resistance, AJCC American Joint Committee on Cancer